turning blood into living drugs
Last Updated : GMT 09:03:51
Almaghrib Today, almaghrib today
Almaghrib Today, almaghrib today
Last Updated : GMT 09:03:51
Almaghrib Today, almaghrib today

New Frontier in Cancer Care

Turning Blood into Living Drugs

Almaghrib Today, almaghrib today

Almaghrib Today, almaghrib today Turning Blood into Living Drugs

Ken Shefveland's body was swollen
London - Al Maghrib Today

Ken Shefveland's body was swollen with cancer, treatment after treatment failing until doctors gambled on a radical approach: They removed some of his immune cells, engineered them into cancer assassins and unleashed them into his bloodstream.

Immune therapy is the hottest trend in cancer care and this is its next frontier — creating "living drugs" that grow inside the body into an army that seeks and destroys tumors.

Looking in the mirror, Shefveland saw "the cancer was just melting away." A month later doctors at the Fred Hutchinson Cancer Research Center couldn't find any signs of lymphoma in the Vancouver, Washington, man's body.

"Today I find out I'm in full remission — how wonderful is that?" said Shefveland with a wide grin, giving his physician a quick embrace.

This experimental therapy marks an entirely new way to treat cancer — if scientists can make it work, safely. Early-stage studies are stirring hope as one-time infusions of supercharged immune cells help a remarkable number of patients with intractable leukemia or lymphoma.

"It shows the unbelievable power of your immune system," said Dr. David Maloney, Fred Hutch's medical director for cellular immunotherapy who treated Shefveland with a type called CAR-T cells.

"We're talking, really, patients who have no other options, and we're seeing tumors and leukemias disappear over weeks," added immunotherapy scientific director Dr. Stanley Riddell. But, "there's still lots to learn."

T cells are key immune system soldiers. But cancer can be hard for them to spot, and can put the brakes on an immune attack. Today's popular immunotherapy drugs called "checkpoint inhibitors" release one brake so nearby T cells can strike. The new cellular immunotherapy approach aims to be more potent: Give patients stronger T cells to begin with.

Currently available only in studies at major cancer centers, the first CAR-T cell therapies for a few blood cancers could hit the market later this year. The Food and Drug Administration is evaluating one version developed by the University of Pennsylvania and licensed to Novartis, and another created by the National Cancer Institute and licensed to Kite Pharma.

CAR-T therapy "feels very much like it's ready for prime time" for advanced blood cancers, said Dr. Nick Haining of the Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard, who isn't involved in the development.

Now scientists are tackling a tougher next step, what Haining calls "the acid test": Making T cells target far more common cancers — solid tumors like lung, breast or brain cancer. Cancer kills about 600,000 Americans a year, including nearly 45,000 from leukemia and lymphoma.

"There's a desperate need," said NCI immunotherapy pioneer Dr. Steven Rosenberg, pointing to queries from hundreds of patients for studies that accept only a few.

For all the excitement, there are formidable challenges.

Scientists still are unraveling why these living cancer drugs work for some people and not others.

Doctors must learn to manage potentially life-threatening side effects from an overstimulated immune system. Also concerning is a small number of deaths from brain swelling, an unexplained complication that forced another company, Juno Therapeutics, to halt development of one CAR-T in its pipeline; Kite recently reported a death, too.

And, made from scratch for every patient using their own blood, this is one of the most customized therapies ever and could cost hundreds of thousands of dollars.

"It's a Model A Ford and we need a Lamborghini," said CAR-T researcher Dr. Renier Brentjens of New York's Memorial Sloan Kettering Cancer Center, which, like Hutch, has a partnership with Juno.

In Seattle, Fred Hutch offered a behind-the-scenes peek at research underway to tackle those challenges. At a recently opened immunotherapy clinic, scientists are taking newly designed T cells from the lab to the patient and back again to tease out what works best.

"We can essentially make a cell do things it wasn't programmed to do naturally," explained immunology chief Dr. Philip Greenberg. "Your imagination can run wild with how you can engineer cells to function better."

TWO LONG WEEKS TO BREW A DOSE

The first step is much like donating blood. When leukemia patient Claude Bannick entered a Hutch CAR-T study in 2014, nurses hooked him to a machine that filtered out his white blood cells, including the T cells.

Technicians raced his bag of cells to a factory-like facility that's kept so sterile they must pull on germ-deflecting suits, booties and masks just to enter. Then came 14 days of wait and worry, as his cells were reprogrammed.

Bannick, 67, says he "was almost dead." Chemotherapy, experimental drugs, even a bone marrow transplant had failed, and "I was willing to try anything."

GENETICALLY ENGINEERING CELLS

The goal: Arm T cells with an artificial receptor, a tracking system that can zero in on identifying markers of cancer cells, known as antigens. For many leukemias and lymphomas, that's an antigen named CD19.

Every research group has its own recipe but generally, scientists infect T cells with an inactive virus carrying genetic instructions to grow the desired "chimeric antigen receptor." That CAR will bind to its target cancer cells and rev up for attack.

Millions of copies of engineered cells are grown in incubators, Hutch technicians pulling out precious batches to monitor if they're ready for waiting patients.

If they work, those cells will keep multiplying in the body. If they don't, the doctors send blood and other samples back to researchers like Riddell to figure out why.

WHAT'S THE DATA?

Small, early studies in the U.S. made headlines as 60 percent to 90 percent of patients trying CAR-Ts as a last resort for leukemia or lymphoma saw their cancer rapidly decrease or even become undetectable. Last week, Chinese researchers reported similar early findings as 33 of 35 patients with another blood cancer, multiple myeloma, reached some degree of remission within two months.

Too few people have been studied so far to know how long such responses will last. A recent review reported up to half of leukemia and lymphoma patients may relapse.

There are long-term survivors. Doug Olson in 2010 received the University of Pennsylvania's CAR-T version for leukemia. The researchers were frank — it had worked in mice but they didn't know what would happen to him.

"Sitting here almost seven years later, I can tell you it works," Olson, now 70, told a recent meeting of the Leukemia and Lymphoma Society.

Bannick, the Hutch patient treated in 2014, recalls Maloney calling him "the miracle man." He had some lingering side effects that required blood-boosting infusions but says CAR-T is "giving me a second life."

SCARY SIDE EFFECTS

"The more side effects you have, that sort of tells everybody it's working," said Shefveland, who was hospitalized soon after his treatment at Hutch when his blood pressure collapsed. His last clear memory for days: "I was having a conversation with a nurse and all of a sudden it was gibberish."

As CAR-T cells swarm the cancer, an immune overreaction called "cytokine release syndrome" can trigger high fevers and plummeting blood pressure and in severe cases organ damage. Some patients also experience confusion, hallucinations or other neurologic symptoms.

Treatment is a balancing act to control those symptoms without shutting down the cancer attack.

Experienced cancer centers have learned to expect and watch for these problems. "And, most importantly, we've learned how to treat them," said Dr. Len Lichtenfeld of the American Cancer Society, who is watching CAR-T's development.

FIGHTING SOLID TUMORS WILL BE HARDER

CAR-Ts cause collateral damage, killing some healthy white blood cells, called B cells, along with cancerous ones because both harbor the same marker. Finding the right target to kill solid tumors but not healthy organ tissue will be even more complicated.

"You can live without some normal B cells. You can't live without your lungs," Riddell explained.

Early studies against solid tumors are beginning, targeting different antigens. Time-lapse photos taken through a microscope in Riddell's lab show those new CAR-T cells crawling over aggressive breast cancer, releasing toxic chemicals until tumor cells shrivel and die.

CARs aren't the only approach. Researchers also are trying to target markers inside tumor cells rather than on the surface, or even gene mutations that don't form in healthy tissue.

"It's ironic that the very mutations that cause the cancer are very likely to be the Achilles heel," NCI's Rosenberg said.

And studies are beginning to test CAR-Ts in combination with older immunotherapy drugs, in hopes of overcoming tumor defenses.

HOW WILL PATIENTS GET THE FIRST CAR-T THERAPIES?

If the FDA approves Novartis' or Kite's versions, eligible leukemia and lymphoma patients would be treated at cancer centers experienced with this tricky therapy. Their T cells would be shipped to company factories, engineered, and shipped back. Gradually, more hospitals could offer it.

Because only certain patients would qualify for the first drugs, others would have to search for CAR-T studies to try the treatment. A drug industry report lists 21 CAR-T therapies in development by a dozen companies.

"This is the hope of any cancer patient, that if you stay in the game long enough, the next treatment's going to be just around the corner," said Shefveland, the Hutch patient.

Source: AFP

almaghribtoday
almaghribtoday

GMT 10:09 2018 Friday ,19 January

Police raid France's Lactalis

GMT 14:20 2018 Thursday ,18 January

Suppressing a sneeze can be dangerous

GMT 12:23 2018 Wednesday ,17 January

Populists target vaccine decree

GMT 12:39 2018 Tuesday ,16 January

Lactalis feels heat as families rebuff

GMT 12:01 2018 Monday ,15 January

Embattled dairy chief breaks silence

GMT 11:26 2018 Sunday ,14 January

One separated Gaza twin dies

GMT 11:31 2018 Saturday ,13 January

France laments 'dysfunction'

GMT 09:22 2018 Friday ,12 January

Cancer shatters gay marriage dreams
Almaghrib Today, almaghrib today

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

turning blood into living drugs turning blood into living drugs

 



Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

turning blood into living drugs turning blood into living drugs

 



Almaghrib Today, almaghrib today Skincare PR Performance Full Year 2017

GMT 09:22 2018 Monday ,22 January

Skincare PR Performance Full Year 2017
Almaghrib Today, almaghrib today New hunt for flight MH370 gets under way

GMT 11:03 2018 Wednesday ,24 January

New hunt for flight MH370 gets under way
Almaghrib Today, almaghrib today Modern colorful bedroom renovation

GMT 10:57 2017 Thursday ,21 December

Modern colorful bedroom renovation
Almaghrib Today, almaghrib today Puigdemont candidate for Catalan president

GMT 13:56 2018 Tuesday ,23 January

Puigdemont candidate for Catalan president
Almaghrib Today, almaghrib today Turkey detains dozens more

GMT 10:47 2018 Wednesday ,24 January

Turkey detains dozens more
Almaghrib Today, almaghrib today The Rake announces editorial updates

GMT 10:46 2018 Tuesday ,16 January

The Rake announces editorial updates
Almaghrib Today, almaghrib today Europe brings on charm and blue skies

GMT 11:51 2018 Tuesday ,23 January

Europe brings on charm and blue skies
Almaghrib Today, almaghrib today For the Variety of Interior Design Styles

GMT 10:46 2017 Tuesday ,19 December

For the Variety of Interior Design Styles
Almaghrib Today, almaghrib today US Christian tourists see deep meaning

GMT 13:44 2018 Monday ,22 January

US Christian tourists see deep meaning
Almaghrib Today, almaghrib today Amazon to open first cashierless shop

GMT 10:03 2018 Tuesday ,23 January

Amazon to open first cashierless shop

GMT 20:21 2017 Saturday ,19 August

Mazad, Arabian Auction announce online auction

GMT 09:48 2011 Thursday ,21 July

Sugar premiums tick lower as prices rise

GMT 11:52 2017 Wednesday ,05 July

Five matches to watch at Wimbledon on day three

GMT 10:08 2017 Monday ,18 December

Stefano:'Don't call me gay'

GMT 14:35 2013 Sunday ,05 May

Rotana board discusses strategy, budget

GMT 01:54 2011 Monday ,26 December

Loud iPods damage hearing

GMT 09:13 2012 Wednesday ,13 June

Karachi traders strike over violence in the city

GMT 21:16 2014 Wednesday ,04 June

Gunmen kill Red Cross official in Libya's Sirte

GMT 21:55 2016 Saturday ,07 May

China is winning war of the worlds

GMT 00:13 2014 Thursday ,23 January

Biofuel from desert plants grown with seawater

GMT 13:05 2011 Thursday ,20 October

Journey to adulthood

GMT 01:12 2012 Wednesday ,10 October

Libya consulate was invaded, torched by armed mob

GMT 19:08 2016 Sunday ,25 December

King condoles Saudi Monarch over death

GMT 12:34 2015 Wednesday ,02 September

PM Ibrahim Mahlab meets 0-grade student

GMT 08:32 2017 Friday ,15 September

Dozens dead in Iraq attack claimed by IS

GMT 16:16 2012 Sunday ,26 February

Range Rover Evoque

GMT 12:32 2011 Tuesday ,04 October

No delay in paying Palestinian employees\' wages

GMT 15:36 2012 Thursday ,20 December

Spain finish 2012 on top, Colombia in 5th

GMT 13:55 2017 Sunday ,05 March

Qatar tourism growth to generate $17.8bn

GMT 22:48 2011 Tuesday ,27 September

Qatar, Algeria hold talks

GMT 10:10 2011 Wednesday ,13 July

UN Human Rights Chief makes working visit to Tunsia

GMT 13:22 2011 Tuesday ,13 December

Mrs. Nixon

GMT 05:43 2012 Tuesday ,17 January

Make sure it\'s in March
Almaghrib Today, almaghrib today
 
 Almaghrib Today Facebook,almaghrib today facebook  Almaghrib Today Twitter,almaghrib today twitter Almaghrib Today Rss,almaghrib today rss  Almaghrib Today Youtube,almaghrib today youtube  Almaghrib Today Youtube,almaghrib today youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

.almaghribtoday .almaghribtoday .almaghribtoday .almaghribtoday
almaghribtoday almaghribtoday almaghribtoday
almaghribtoday
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
almaghribtoday, Almaghribtoday, Almaghribtoday